Wafik S. El-Deiry, MD, PhD, FACP

Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.

Wafik S. El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, William Wikoff Smith Chair in Cancer Research, American Cancer Society Research Professor, discusses the importance of understanding tumor heterogeneity an interview during the 2017 ASCO Annual Meeting.